Company Profile

Pandomedx Inc
Profile last edited on: 4/27/2018      CAGE: 7B6W9      UEI: EMMVLVGAKYK6

Business Identifier: Therapeutic targets for prostate cancer
Year Founded
2015
First Award
2016
Latest Award
2019
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

611 Robin Place
Davis, CA 95616
   (530) 419-5989
   N/A
   N/A
Location: Single
Congr. District: 03
County: Yolo

Public Profile

A startup coming out of University of California Davis is organized around identifying therapeutic targets for prostate cancer. In collaboration wit University of Califoria Davis, Pandomedx undertook Phase I trial to study the best dose and side effects of niclosamide when given together with enzalutamide in treating patients with castration-resistant prostate cancer that has come back or has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androgen by the tumor cells. Niclosamide may block signals that enhance prostate cancer cell growth. Giving enzalutamide and niclosamide may work better in treating patients with castration-resistant prostate cancer.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Allen C Gao

  Chengfei Liu

Company News

There are no news available.